Press release
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
– Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU - –
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU -\n\n– Real-word evidence and patient survey data demonstrate treatment burden associated with the administration of injectable on-demand treatments in HAE -\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.\n\nThe following presentations occurred at the 2023 AAAAI Annual Meeting:\n\n\nA comparative bioavailability of sebetralstat following administration of orally disintegrating tablets and film-coated tablets in healthy volunteers: Michael D. Smith, KalVista Pharmaceuticals Inc., Cambridge, MA, USA\n\n\nReporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022: Dr. Raffi Tachdjian, UCLA School of Medicine, Los Angeles, CA, USA\n\n\nAnxiety Associated With Parenteral On-Demand Treatment For Hereditary Angioedema (HAE): Dr. Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, USA\n\n\nPatient Perspectives On Early Use Of On-Demand Treatment For Hereditary Angioedema (HAE) Attacks to Reduce Severity and Duration: Dr. Cristine Radojicic, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina, USA\n\n\nTreatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial: Dr. Jonathan A. Bernstein, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, OH, USA\n\n\n“The real-world data presented at AAAAI highlight the significant treatment burden and anxiety associated with existing injectable on-demand therapies, and the potential for sebetralstat, an investigational oral plasma kallikrein inhibitor, to improve the treatment experience for people living with HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “Additionally highlighting this potenti...